Cervical cancer and the need for a bedside assay {#Sec1}
================================================

Current diagnosis of cervical cancer: the need for triage {#Sec2}
---------------------------------------------------------

Considering cervical cancer is the fourth most common female cancer worldwide, it remains a significant global problem \[[@CR1]\], indicating that better screening and adequate interventions are necessary to reduce mortality. On the other hand, HPV vaccines offer the potential to significantly reduce the incidence of infection with an oncogenic high-risk (hr) HPV type, the causative agent for cervical cancer. Currently, two HPV vaccines are commercially available, Cervarix (GlaxoSmithKline) and Gardasil (Merck & Co). Cervarix is (cross)reactive against HPV types-16, -18, -31, -33, -45, -51 and -56, which are the seven most common cancer-causing types \[[@CR2]\]. Gardasil is effective against HPV-16, 18 and 31, and this vaccine is also effective against HPV-6 and -11, which cause genital warts and respiratory papillomatosis \[[@CR2]\]. A nonavalent vaccine (Gardasil 9) was recently approved that protects against nine different types of HPV (types 6, 11, 16, 18, 31, 33, 45, 52 and 58) \[[@CR3]--[@CR5]\].

However, despite the advancements in HPV vaccination, these vaccines do not cover all hr-HPV types \[[@CR6]\] and are less efficient in women who were previously infected with HPV \[[@CR7]\]. Together with the lack of HPV vaccination programs in many low-resource countries, these observations indicate the lasting need for population-wide cervical cancer screening programs, which further requires accurate diagnosis of the disease. Moreover, cautiously monitoring \[[@CR8]\] vaccination programs also demands accurate detection methods.

The gradual development of cervical cancer (years) with the occurrence of several precancerous stages and the relative ease with which the tumor can be accessed offer the opportunity to screen population-wide for cervical cancer during prevention campaigns. Cervical cancer screening programs are generally based on the detection of hr-HPV via DNA or RNA assays or on the detection of cytological and/or molecular changes in cervical cells via (immuno)staining methods, such as the Papanicolaou (Pap) smear \[[@CR8]\].

High-risk HPV DNA-based PCR tests are currently of high interest because they are 40% more sensitive at detecting a cervical abnormality than cytology \[[@CR9], [@CR10]\]. However, despite their higher sensitivity, these assays cannot distinguish between clinically relevant HPV infections. Indeed, approximately 80% of hr-HPV infected women spontaneously clear the virus within 1 year after acquisition \[[@CR11]\], resulting in significant overtreatment of hr-HPV-infected women.

Cytology-based screening has several other limitations, such as the high intra- and interobserver variability, limited sensitivity, high costs and limited screening coverage \[[@CR12]--[@CR14]\]. Currently, cytology/HR-HPV DNA co-testing remains the best strategy for detecting high-grade cervical vaginal lesions \[[@CR15]\]. In the case of positive test results, the patient is usually referred to the clinic for a colposcopy examination that detects changes in the glycogen metabolism in cervical (pre)cancerous cells \[[@CR16]\].

The conclusion is that because of the limitations of each of these methods, screening programs are never 100% safe (false negatives). Moreover, they are subject to oversampling (high number of false positives), leading to the treatment of women with clinically irrelevant hr-HPV infections, which increases the costs and possible harm caused by the treatment. Additional triage tests, on a molecular basis, are thus necessary to provide an objective and reproducible basis for the selection of patients with clinically significant disease. Today, the best alternative is dual staining for p16^INK4a^/Ki-67 \[[@CR17]--[@CR19]\], but this method may have an increased cost and previous work has demonstrated that p16 may not have sufficient discriminatory power because normal cells also express p16 (albeit at lower levels) \[[@CR20]\]. Therefore, alternative methods, such as the combination stainings of TOP2A and Ki-67 \[[@CR21]\] or p16^INK4a^/Ki-67 and L1 capsid protein \[[@CR22]\], are being sought. Unfortunately, biomarkers with good predictive values (e.g., predicting progress towards cervical carcinoma while appearing at the CIN2 stage, which still allows for treatment) do not exist yet (reviewed by \[[@CR23]--[@CR25]\]). Moreover, it is expected that a panel of biomarkers will be necessary for an accurate test that distinguishes between the several CIN states with good clinical sensitivity and specificity. Preferentially, such combined biomarkers are unrelated, e.g., molecules from different cervical cancer pathways, cancer- vs. immune-related molecules, proteins vs. (methylated) nucleic acids, such that the assay is based on a broad series of independent recognition points.

CVF as a candidate body fluid for cervical cancer screening by self-testing {#Sec3}
---------------------------------------------------------------------------

### Self-sampling {#Sec4}

In 2014, Arbyn et al. \[[@CR26]\] showed that hr-HPV DNA testing on a self-sample is a way to include women who normally do not participate in regular cytology screening programs. Indeed, self-sampling has proven effective in increasing participation and screening coverage of the target population \[[@CR27]--[@CR32]\]. Many studies performed in different ethnic populations have demonstrated that self-sampling of cervical tissue via brushes, tampons, swabs or lavages is a good sample collection method for subsequent DNA genotyping, cytology or immunohistochemistry \[[@CR26], [@CR33]--[@CR38]\]. The sampled tissue is usually resuspended in liquid buffer \[[@CR39]--[@CR42]\], although dry storage is also considered, e.g., by capping the brush \[[@CR43]\] or by swiping the sample on paper that was chemically treated with reagents to lyse cells upon application so that they are non-infectious for safe and easy transport \[[@CR44]--[@CR47]\]. The samples are then sent to the laboratory for further analysis.

Using the emerging proteomics technologies that have become increasingly sensitive, our group and others groups have conducted several studies on the identification of the cervical vaginal proteome \[[@CR48]--[@CR65]\]. Functional classification of the CVF proteome demonstrates a significant diversity of biological roles, of which "protein metabolism and modification" and "immunity and defense" are the largest GO categories (17 and 10%, respectively). Moreover, classification based on cellular localization shows that most proteins are present in the cytoplasm or in the extracellular region (21 and 20%, respectively) \[[@CR57]\].

Because of the immediate contact of the precancerous or cancerous tissue with the CVF, we expect that the concentrations of important cervical cancer biomarkers will be high in CVF. Unlike plasma, CVF does not contact many other tissues, and its volume is limited (milliliters versus liters). Moreover, the liquid can easily be collected by self-sampling in a non-invasive way using devices for lavages \[[@CR36], [@CR66]\], or using tampons \[[@CR38], [@CR67]\] (self-sampling devices developed before 2014 were reviewed in Othman et al. \[[@CR68]\]). Therefore, self-sampling of CVF could overcome the practical (e.g., busy schedule, transport, and distance), emotional (e.g., fear of pain and embarrassment), and cognitive (e.g., low perceived risk and absence of symptoms) barriers that some women experience in attending cervical cancer screening programs \[[@CR69]--[@CR71]\]. Ideally, the same, self-collected sample should be used for the detection of several biomarkers, demanding minimal effort from women.

### Self-testing {#Sec5}

Especially in low-resource countries and remote rural areas where mail and transport are much less frequent, the continuous running of an efficient screening program for cervical cancer may demand organizational, financial and logistical efforts \[[@CR72], [@CR73]\] that may not always be available. A simple test, such as a lateral flow assay (LFA) that could be performed by the woman herself could be a solution to this problem because it does not require specialized instruments or personnel, and it could be performed at home or e.g., at a doctor\'s practice (point-of-care). LFA assays are frequently used to detect a variety of clinical analytes in plasma, serum, urine, cells, tissues and other biological samples and are also used for veterinary and industrial purposes \[[@CR74]--[@CR76]\]. Although efforts have been made to develop LFA tests for detecting HPV DNA from precancerous tissue \[[@CR77]\], detection of proteins would be most suitable. Indeed, because of the frequent spontaneous elimination of the lesion, the presence of HPV virus does not always correspond with the presence of (pre)cancerous tissue. On the other hand, detection of proteins from precancerous cervical tissue in the cervical vaginal fluid would directly indicate the presence of such tissue. If such biomarkers could distinguish between the three CIN stages, a manual could inform the patient about whether to see a doctor. To avoid inclusion of a cell lysis step, which would compromise ease of handling, detection of secreted and/or released proteins from the precancerous lesions into the CVF is recommended for LFA.

A typical example of an LFA test that is already on the marked, is the self-test for HIV (HIVST). According to the WHO such a test used and interpreted by a self-tester can perform as well as an HIV RDT used and interpreted by a trained health worker \[[@CR78]\] although concerns remain about test sensitivity (particularly in early infection), and linkages to care for confirmatory testing after a reactive HIVST \[[@CR79]\]. Nevertheless, HIVST is likely to become more widely available, including in low- and medium-income countries, as it is generally accepted among key populations \[[@CR80]\] and, therefore, has the potential to drastically increase HIV testing coverage. It is, therefore, quite possible that the HIVST LFA assay is a trendsetter in human self-diagnostic medicine.

In summary, we believe that CVF is a rich source of information regarding the physiological status of the female genital organs, including the healthy or cancerous state of the cervical region. Components from the CVF could, therefore, be used as the basis for a simple self-test/point-of-care test that, when sufficiently accurate, may overcome current problems with coverage and specificity.

CVF biomarkers for cervical cancer {#Sec6}
==================================

HPV DNA assay {#Sec7}
-------------

Many studies report on the efficiency of HPV DNA testing from self-collected cervical tissue samples, compared to samples collected by a practitioner. In most studies, HPV testing on self- and clinician-sampled specimens is similarly accurate with respect to CIN2+ detection as reported in a large cohort study \[[@CR42], [@CR81]\] or a meta-analysis \[[@CR33]\], although this may depend on the test used \[[@CR26]\].

As for detection of HPV DNA from cervical vaginal fluid there was a high agreement between the (self-sampled) CVF and the reference smears (between 89 and 93%, depending on the test used) \[[@CR82]\] and no difference in viral load was observed when samples were collected in the estrogen-dominated proliferative phase or the progesterone-dominated secretory phase \[[@CR83]\].

Unfortunately, HPV DNA detection requires very specialized equipment (in the previous study, a Roche cobas 4800 system); therefore, it is not suited for a self-test. Furthermore, as mentioned above, the test cannot distinguish between productive and progressive infections, resulting in a low specificity.

Host and viral DNA methylation {#Sec8}
------------------------------

With the discovery that global DNA hypomethylation progressively increases in cervical dysplasia and carcinoma \[[@CR84]\], Widschwendter et al. \[[@CR85]\] investigated DNA methylation in cervical vaginal specimens collected on a tampon of 11 host genes known to be methylated in cervical cancer (*SOCS1*, *CDH1*, *TIMP3*, *GSTP1*, *DAPK*, *hTERT*, *CDH13*, *HSPA2*, *MLH1*, *RASSF1A*, and *SOCS2)* and reported a correlation of the methylation status with the severity of the cervical lesion, such that invasive cervical cancers could be predicted. Along the same line, Sun and coworkers \[[@CR86]\] analyzed in cervical vaginal lavages methylation at 14 CpG sites within the HPV16 L1 region and noticed a significant increase in methylation in samples from women with CIN3+ compared to the HPV16 genomes from women without CIN3+, indicating that hyper/hypomethylation of viral CpG sites may constitute a potential biomarker for precancerous and cancerous cervix disease \[[@CR86]\]. In a high-throughput experiment using the Illumina 450 k DNA methylation array, Doufekis et al. \[[@CR87]\] investigated the DNA methylation in vaginal fluid samples at more than 480,000 CpG sites and found a DNA methylation signature for cervical and endometrial cancer which resulted in a ROC area under the curve between 0.75 and 0.83.

DNA methylation of miRNA {#Sec9}
------------------------

MicroRNAs have not only been detected in the serum or plasma of patients who are precancerous for cervical cancer (cervical adenocarcinoma and squamous cell cancer) \[[@CR88]\], they have also been detected in CVF. In a large, randomized study of self-sampled cervical vaginal fluid, Verhoef et al. \[[@CR89], [@CR90]\] investigated direct DNA methylation of miR-124-2 and MAL genes on samples that tested positive for HPV and showed that DNA methylation analysis is non-inferior to cytology triage in the detection of CIN2 or higher. 2 years later, the combination of miR-124-2 methylation and methylation of another gene, FAM19A4, was investigated in a large cohort of HPV positive women by the same group \[[@CR91]\]. The accuracy of the assay was similar for CVF self-collected samples and for clinician-collected cervical smears.

Exosomes {#Sec10}
--------

Interestingly, after silencing HPV E6/E7 oncogene expression in HPV-positive cervical cells, such as HeLa cells, a distinct seven-miRNA-signature was identified in the exosomes secreted by the HeLa cells, which was accompanied by significant downregulation of let-7d-5p, miR-20a-5p, miR-378a-3p, miR-423-3p, miR-7-5p, miR-92a-3p and upregulation of miR-21-5p \[[@CR92]\]. Later, similar results were obtained in keratinocytes transduced with E6 and E7 from mucosal HPV-16 or cutaneous HPV-38 \[[@CR93]\]. This raised the idea of using CVF-derived exosomes for diagnostic purposes. Indeed, Liu et al. \[[@CR94]\] described microRNA-21 and microRNA-146a to be upregulated in cervical cancer patients in association with the high levels of cervical cancer-derived exosomes in CVF, and Zhang et al. \[[@CR95]\] recently showed that expression of the HOTAIR, MALAT1 and MEG3 long noncoding RNAs (lncRNAs) was predominantly observed in cervical cancer-derived exosomes in cervical vaginal lavage samples.

Hence, it is clear that DNA methylation or RNAs could serve as a CVF biomarker for intraepithelial cancerous lesions; however, analogous to DNA PCR, a methylation-specific or RNA-specific PCR reaction requires skilled people and specialized instruments, making it unsuitable for self-testing.

First discovered protein markers {#Sec11}
--------------------------------

The discovery that carcinoembryonic antigen (CEA), CA19-9 and CA125 were present in the CVF of patients with cervical cancer or with a cervical precancerous lesion led to optimism in the 80 s that these biomarkers could help in detecting cervical cancer or its precancerous stages \[[@CR96]--[@CR99]\]. Later, it was found that these antigens were normal constituents of vaginal fluid and that their distribution was not only affected by cancer of the genital tract but also by pregnancy \[[@CR100], [@CR101]\] and inflammation \[[@CR102]\], limiting their applicability for use as biomarkers. Nevertheless, the presence of CA125 in the CVF has also been correlated with endometrial cancer \[[@CR103]\].

Immunological proteins {#Sec12}
----------------------

In a later study \[[@CR104], [@CR105]\], in 60% of the patients with HPV 16 positive cervical cancer, anti-HPV 16 E7 specific IgG antibodies were found in cervicovaginal washings and sera, while no IgG reactivity was found in healthy individuals. Moreover, IgG antibody reactivity in cervicovaginal washings was higher than in the paired serum samples. Nevertheless, because the presence of these antibodies was less clear in premalignant tissue and since they could only be detected in 60% of the patients, the sensitivity and specificity are not sufficient for biomarker purposes. The same group analyzed the presence of various cytokines in cervicovaginal washings of healthy volunteers, CIN patients and cervical cancer patients and demonstrated alterations in the local cervical immune environment in cervical cancer patients. Indeed, the IL-12p40, IL-10, TGF-beta1, TNF-alpha and IL-1beta levels were significantly higher in patients with cervical cancer than in controls and CIN patients \[[@CR106], [@CR107]\]. Although these results are of interest for the development of immune modulating therapies and vaccination strategies, they cannot be used for diagnostic applications because no differences were seen between CIN patients, and the cytokine levels may vary according to other infections.

Since then, many studies were undertaken to identify cervical (pre)cancer protein biomarkers from swab samples or biopsies \[[@CR23]--[@CR25], [@CR108], [@CR109]\], yet no other cervical cancer biomarker proteins were found in the CVF.

Alpha-actinin-4 {#Sec13}
---------------

### Discovery {#Sec14}

In a differential proteomics study on CVF samples from six healthy and six precancerous (CIN I, II and III) women, we identified 16 candidate biomarkers (\[[@CR63]\], Table [1](#Tab1){ref-type="table"}). From these, alpha-actinin-4 (ACTN4) was absent and present in all samples from healthy and precancerous women (*p* = 0.001), respectively. ELISA on 28 additional samples showed a discriminatory potential of ACTN4 at 18 pg/ml protein extract between samples from healthy and both low-risk and high-risk HPV-infected women (*p* = 0.009). Analyzing the ACTN4 concentration in 26 CVF samples originating from longitudinal studies on 9 women who experienced an HPV infection, who had a persistent infection or who cleared the virus showed that the ACTN4 levels correlated with increasing, persisting or decreasing presence of HPV E6 DNA \[[@CR63]\].Table 1Samples used for calculating the ACTN4 discriminatory power as a biomarker for cervical (pre)cancerCohortSampleGroupConditionGenotypeViral load (copies/cell)ColposcopyCytologyCollection mediumACTN4 (/mg prot)Van Raemdonck et al. \[[@CR63], [@CR64]\]H07HealthyHPV negNormalNormal5% AA42.8H12HealthyHPV negNormalNormal5% AA0.6H52HealthyHPV negNormalNormal5% AA6.1H54HealthyHPV negNormalNormal5% AA1.9H62HealthyHPV negNormalNormal5% AA7.2H20HealthyHPV negNormalNormal5% AA0.5H05HealthyHPV negNormalNormal5% AA3.1H64HealthyHPV negNormalNormal5% AA3.6H28HealthyHPV negNormalNormal5% AA0.0H69HealthyHPV negNormalNormal5% AA5.3H70HealthyHPV negNormalNormal5% AA0.1H08HealthyHPV negNormalNormal5% AA8.7H14HealthyHPV negNormalNormal5% AA7.5H73HealthyHPV negNormalNormal5% AA3.5H87HealthyHPV negNormalNormal5% AA0.0H90HealthyHPV negNormalNormal5% AA8.2H09Low risk696,249ASCUSNormal5% AA12.7H35Low risk1151,740ASCUSCIN15% AA10.7H182Low risk61.00NormalNormal5% AA20.7H213Low risk60.05NormalNormal5% AA29.9P24High risk16/397729/1661ASCUSCIN35% AA17.1P27High risk52129LSILCIN15% AA113.9P60High risk16/31/52/660.02/11/12/31LSILCIN15% AA32.6P61High risk16/31/39/52/66288/0.20/4/7416/179LSILCIN15% AA22.2P41High risk16/5811571/253HSILCIN25% AA45.0P36High risk16/53/58/599126/79/2733/1510LSILCIN15% AA70.4P70High risk355159LSILCIN25% AA15.3P40High risk311696HSILCIN15% AA15.5Additional samples (cohort Van Raemdonck et al. \[[@CR63]\])205HealthyHPV negNormal5% AA0.0207HealthyHPV negNormal5% AA0.0211HealthyHPV negNormal5% AA0.0212HealthyHPV negNormal5% AA0.0229HealthyHPV negNormal5% AA36.1206High riskHPV negASCUS5% AA154.5204High risk45LSIL/HSIL5% AA0.0210High risk16LSIL5% AA52.1224High risk18/39/56LSIL5% AA0.0225High risk56LSIL5% AA0.0Van Raemdonck et al. \[[@CR63], [@CR64]\] (longitudinal samples)42Patient L1High risk new infection52/53/59/66178/0.07/50/6LSIL5% AA0.51195226.00Normal5% AA5.030816/52171/283ASCUS5% AA22.785Patient L2High risk clearing33/52/58/660.01/9147/268/526LSIL5% AA32.1146HPV neg0.00LSIL5% AA11.2281HPV neg0.00Normal5% AA0.536Patient L4High risk persisting16/53/58/599126/79/2733/1510LSIL5% AA17.710516/53/5899,999/11/4123LSIL5% AA37.117216/583/99,999LSIL5% AA39.7290584997.00LSIL5% AA46.0154Patient L5HealthyHPV neg0.00Normal5% AA4.2242310.62Normal5% AA0.5302HPV neg0.00Normal5% AA2.015Patient L6High risk clearing16/39/532627/12,052/0.51LSIL5% AA10.1135164.00Normal5% AA0.52711633.00Normal5% AA1.8S266Patient L7High risk clearing16/31/51/56111/0.2452/33/271LSIL5% AA15.023HPV neg0.00Normal5% AA0.5127HPV neg0.00Normal5% AA3.1359HPV neg0.00Normal5% AA1.343Patient L8High risk new infectionHPV neg0.00Normal5% AA0.514751/5999,999/46LSIL5% AA17.434851/590.13/165ASCUS5% AA7.270Patient L9High risk clearing355159.00HSIL5% AA6.3177HPV neg0.00Normal5% AA0.6342HPV neg0.00Normal5% AA0.5103Patient L10High risk persisting31351.00Normal5% AA18.1218311556.00Normal5% AA25.0343313479.00ASCUS5% AA60.8Berlin cohortDS77High risk16/31/52CIN3PBS0.0DS78High risk16CIN3PBS896.2DS72Cancerous16CxCaPBS782.9DS73CancerousHPV negCxCa after conisationPBS719.0DS80Cancerous18/56Cx AdenoCaPBS355.2DS86Cancerous16CxCaPBS463.8DS90CancerousHPV negCxCa FIGO IIIb N1 (1/10)PBS559.0DS74Cancerous16CxCa 1a1 VAIN IIIPBS2316.7DS79Cancerous16ZxCa susp. PeritonealPBS3075.2DS84CancerousHPV negCxCaPBS500.0DS87CancerousHPV negCxCa pT1a2 G2 L1 V0 R1PBS178.1DS88Cancerous16CxCa FIGO IIaPBS949.2DS89Cancerous16CxCa FIGO IIbPBS1354.8DS91Cancerous18/43CxCa FIGO libPBS636.4Van Raemdonck et al. \[[@CR64]\]5714No HIVESN populationHPV neg----PBS2.53896No HIVESN populationHPV neg----PBS4.26624HIVESN populationHPV neg----PBS0.06589HIVESN populationHPV neg----PBS0.06488HIVESN populationHPV neg----PBS0.0Three different cohorts were included with a varying CVF sample size and collection medium. A series of samples from the first cohort consisted of 28 singular samples and samples taken at different time points from 9 patients (longitudinal samples) \[[@CR63]\]. These were further supplemented with ten additional singular samples from the same cohort. Fourteen samples were from another cohort (Charité, Berlin; Charite IRB Ethics Approval EA02/129/08), consisting of samples from two women with CIN III and twelve women with different stages of cervical cancer. We also included five CVF samples from a previously described cohort \[[@CR64]\]. From this cohort, all samples were HPV-negative, as demonstrated by RT-PCR genotyping \[[@CR161]\], and three of them came from HIV-positive women. Classification was made based on colposcopy examination and/or cytology results. In case both examinations gave conflicting results, colposcopy results had priority. Samples from healthy individuals were given a gray background. Since the study by Van Raemdonck et al. \[[@CR64]\] lacked colposcopy and cytology, the absence of (pre)cancerous tissue was decided on the basis of HPV absence

### Alpha-actinin-4 and cancer {#Sec15}

Alpha-actinin-4 is predominantly expressed in cellular filopodia and lamellipodia, and as such, it is important for the formation of cell protrusions and migration \[[@CR110]\]. Experiments in colon and pancreatic cancer cells have shown that ACTN4 overexpressing cells are highly mobile and have a significantly increased metastatic ability \[[@CR111]--[@CR114]\]. Apart from in colorectal and pancreatic cancer, the protein is also overexpressed in ovarian cancer, osteosarcoma, lung cancer, oral squamous cell carcinoma, salivary gland carcinoma, bladder cancer, breast cancer and esophageal cancer (for an overview, see \[[@CR115]\]). ACTN4 gene amplifications were shown to correlate with pancreatic cancer \[[@CR113]\] and could be a potential biomarker for metastatic potency and for predicting the effectiveness of chemoradiotherapy in locally advanced pancreatic cancer \[[@CR116]\]. Elevated levels of ACTN4 contribute to the increased migratory potential of neuroblastomas \[[@CR117]\]. Worsened survival rates were seen in ACTN4 overexpressing ovarian tumors \[[@CR118]\]. Moreover, studies have demonstrated that in addition to its role in cytoskeleton remodeling, ACTN4 interacts with signaling mediators, chromatin remodeling and transcription factors. Nuclear localization of the protein was seen in different tumors \[[@CR110], [@CR119], [@CR120]\], and recruitment of ACTN4 to the *pS2* promotor, an estrogen receptor (ER) target in the ER-positive breast cancer cell line MCF7, suggested that ACTN4 may play a role in E2-mediated regulation of breast cancer proliferation \[[@CR121], [@CR122]\]. Interestingly, ACTN4 has been reported to be present in exosomes from tumor (mesothelioma) cells \[[@CR123]\]. ACTN4 thus functions as a promoter for many tumor types and could be an important target protein in drug development. Therefore, it is not surprising to see the protein appearing in the cervical vaginal fluid of women who have cervical precancerous lesions. ACTN4 may, therefore, play an important role in the development of a simple bedside assay for cervical cancer based on CVF components.

### Efficiency of alpha-actinin-4 as a CVF biomarker for cervical cancer {#Sec16}

For a preliminary determination of the sensitivity and specificity of ACTN4 as a cervical (pre)cancer biomarker, we extended our sample pool with 10 CVF samples from the previous cohort \[[@CR63]\], 14 CIN III or cervical cancer samples from a Berlin cohort (see Table [1](#Tab1){ref-type="table"}) and five samples from an African cohort, three of which were from women infected with HIV-1 \[[@CR64]\] (Table [1](#Tab1){ref-type="table"}). Based on colposcopic determination of the precancerous state, we divided the samples into two classes. The first class (*N* = 43) contained samples originating from healthy women, while the second class (*N* = 43) contained samples originating from women with small (ASCUS, LSIL) or larger (HSIL) signs of precancerous tissue or with cancerous tissue. Because the samples came from different hospitals in different volumes, we took the total mass of protein as a reference instead of the sample volume. For this normalization, the ACTN4 concentration was recalculated as pg/mg total protein instead of pg/ml. The resulting ROC curve showed an AUC of 86% (Fig. [1](#Fig1){ref-type="fig"}) with a sensitivity (true positives/true positives + false negatives) and specificity (true negatives/true negatives + false positives) of 84 and 86%, respectively, when a cutoff value of 10 pg ACTN4/mg total protein was used. It must be mentioned that this value was obtained despite differences in the volumes and collection media resulting from the inclusion of different cohorts. Because only a limited number of samples from women with precancerous tissue above CIN II or CIN III were included in this study (*N* = 6), it was not possible to correlate the ACTN4 concentration with different CIN stages. However, clear overexpression of ACTN4 was visible in all cancerous samples. Interestingly, none of the three samples from HIV-1 infected (HPV negative) individuals scored above the cutoff value, suggesting that HIV-1 infection does not interfere with the ACTN4 levels in CVF. Studies in our lab are currently ongoing to examine the correlation of the ACTN4 concentration with the CIN stages and to evaluate the CVF concentration in women infected with additional sexually transmitted viruses, bacteria and protozoa.Fig. 1ACTN4 ROC curve for discrimination between the healthy and anomalous (ASCUS, CIN I and higher) state. Data from Table [1](#Tab1){ref-type="table"} were used. Numbers of samples for healthy and anomalous state were 48 and 43, respectively. The ROC curve was created by SPSS with inclusion of cutoff values for positive classification. Sensitivity and specificity values were, respectively, 84 and 86% when a cutoff value of 10 pg ACTN4/mg total protein was used, resulting in an area under the curve (AUC) of 86%

Network biomarkers {#Sec17}
------------------

Assuming that precancerous tissue is (partially) attacked by the immune system, we hypothesized that ACTN4 is released in the CVF from lysed epithelial cells with many other intracellular factors, including those involved in the development of precancerous lesions and/or cervical cancer. Aberrant concentrations of (some of) these factors in the CVF may indicate there is growing precancerous tissue and, therefore, an increased chance of developing a malignant tumor. Therefore, starting from the protein lists we obtained from the differential proteomics study on CVF from healthy and precancerous patients \[[@CR63]\], protein IDs (Table [2](#Tab2){ref-type="table"}) were introduced into the Ingenuity Pathway Analysis (IPA) program, and common pathways were searched \[[@CR124]\]. Interestingly, proteins in CVF from precancerous women interconnected much more inside pathways that make up the 'hallmarks of cancer' described by Hanahan and Weinberg \[[@CR125]--[@CR127]\] compared to CVF proteins from healthy people. In addition, a literature search showed that CVF proteins classified by IPA in the 'cancer' category were more correlated with cervical cancer when they originated from the CVF of precancerous women. Moreover, many of these proteins clustered in a network with angiotensin II as a central mediator \[[@CR124]\], and further IPA studies showed their overrepresentation in the following four clusters of pathways that belong to a cancer hallmark: (1) gluconeogenesis/glycolysis, (2) adenine/guanine metabolism, (3) adherens/tight junction formation and 4) a larger set of interconnected pathways clustered around the p70^S6K^ pathway (Fig. [2](#Fig2){ref-type="fig"}). The first two clusters are a result of increased metabolism, a typical feature of tumor cells. Interestingly, the p70^S6K^ pathway has been described to be involved in cell motility \[[@CR128]\]; hence, the two last pathway clusters influence the migration of cells and concomitant metastatic activity. Indeed, an altered expression of tight and adherens junction proteins was frequently reported in cervical neoplasia \[[@CR129]--[@CR131]\], and Claudin-1, a component of tight junction strands, was recently described as having similar diagnostic potential as p16^INK4a^ in histological and cytological biomarker assays for cervical cancer detection \[[@CR132]\]. Additionally, the association of ACTN4 with adherens junction formation has been described \[[@CR110], [@CR133]\]. Such 'network biomarkers', rather than single biomarkers, could increase the accuracy and prognostic value of cervical cancer diagnosis and allow us to better identify the early presence of the tumor, tumor type, and development state.Table 2Proteins that differ in CVF abundance between healthy individuals and individuals with cervical precancerous tissue (CIN I or higher)NameAcc. NoIDIncreased levels in CVF from women with adenocarcinoma: Fujii et al. \[[@CR98]\], Harlozinska et al. \[[@CR97]\] and McDicken et al. \[[@CR96]\]  Carcino embryonic antigen (CEA)Q13984Q13984_HUMAN  carbohydrate antigen disialyl Lewis a, CA19-9Q969X2SIA7F_HUMANIncreased levels in CVF from women with precancerous lesions with stringent selection (*p* \< 0.05) Van Raemdonck et al. \[[@CR63]\]  14-3-3 protein epsilonP622581433E_HUMAN  Actin-related protein 3P61158ARP3_HUMAN  Alpha-actinin-4O43707ACTN4_HUMAN  Annexin A2P07355ANXA2_HUMAN  ATP synthase subunit beta, mitochondrialP06576ATPB_HUMAN  Cellular retinoic acid-binding protein 2P29373RABP2_HUMAN  Nicotinamide phosphoribosyltransferaseP43490NAMPT_HUMAN  Phosphoglycerate kinase 1P00558PGK1_HUMAN  Putative elongation factor 1-alpha-like 3Q5VTE0EF1A3_HUMAN  Pyruvate kinase isozymes M1/M2P14618KPYM_HUMAN  Serpin B13Q9UIV8SPB13_HUMAN  Squamous cell carcinoma antigen 1 (SCCA-1); Serpin B3P29508SPB3_HUMANExclusive occurrence in CVF from women with precancerous lesions and described to be involved in cervical cancer Van Raemdonck et al. \[[@CR63]\] and Van Ostade et al. \[[@CR125]\]  14-3-3 protein thetaP273481433T_HUMAN  AngiotensinogenP01019ANGT_HUMAN  Annexin A4P09525ANXA4_HUMAN  Cathepsin BP07858CATB_HUMAN  CD59 glycoproteinP13987CD59_HUMAN  CeruloplasminP00450CERU_HUMAN  GelsolinP06396GELS_HUMAN  High mobility group protein B2P26583HMGB2_HUMAN  Interleukin-18Q14116IL18_HUMAN  Macrophage migration inhibitory factorP14174MIF_HUMAN  Macrophage-capping proteinP40121CAPG_HUMAN  Mucin-5BQ9HC84MUC5B_HUMAN  Myosin light polypeptide 6P60660MYL6_HUMAN  Phosphoglycerate mutase 1P18669PGAM1_HUMAN  Protein disulfide isomerase A3P30101PDIA3_HUMAN  Protein S100-PP25815S100P_HUMAN  Serpin B13Q9UIV8SPB13_HUMAN  Superoxide dismutase \[Mn\]P04179SODM_HUMANFrom the list of proteins identified in Van Raemdonck et al. \[[@CR63]\], the following two subsets were distinguished: (1) proteins that were, to a high extent (*p* \< 0.05), qualitatively or quantitatively different in the samples from precancerous women compared to the samples from healthy women and (2) proteins that, to a lower extent, qualitatively differed from the samples in precancerous women (presence in at least one of the six 'precancerous' samples, while not present in the 'healthy' samples), which were described to be interconnected and to play a role in cervical cancer \[[@CR124]\] Fig. 2Overlap of canonical pathways containing proteins from Table [2](#Tab2){ref-type="table"} after IPA Core Analysis. The degree of grayness defines the *p* value, where deeper red stands for the lowest*p* values. All *p* values are \< 0.05. The numbers accompanying edges represent common proteins within the 2 connected canonical pathways

Perspectives {#Sec18}
============

Microbiome {#Sec19}
----------

Over recent decades, a substantial amount of work has been done on the characterization of the vaginal microbiome in relation to several diseases. Two groups \[[@CR134], [@CR135]\] described the beneficial role of *Lactobacillus* species in vaginal and reproductive health, while overgrowth of *G. vaginalis*, *A. vaginae*, *Eggerthella*, *Prevotella*, *BVAB2* and *Megasphaera type 1* as well as a marked depletion of *Lactobacillus* were essential for the diagnosis of BV \[[@CR136]\]. In a review by Datcu et al. \[[@CR137]\], it was shown that subgroups of bacterial vaginosis (BV) could be identified wherein single or paired bacteria were dominant.

Several studies have also pointed to a correlation of microbiota with HPV and cervical (pre)cancer. Compared to HPV-negative women, the vaginal bacterial diversity of HPV-positive women is more complex  \[[@CR138]\], and because of an association between the cervical microbiota and CIN stages, the combined effect of the microbiota and HPV on the risk of CIN could be determined \[[@CR139]\]. Moreover, Mitra et al. \[[@CR140]\] showed an association of increasing CIN stage with increasing vaginal microbiota diversity, suggesting a role for microbiota in regulating viral persistence and disease progression. Such changes may be reflected in the expression levels of microbial enzymes, considering Dasari and coworkers \[[@CR141]\] demonstrated that the microbial enzymes mucinase, sialidase, and protease were significantly (*p* \< 0.01) elevated in patients with cervical dysplasia and, therefore, may serve as risk-factors for the development of cervical cancer.

Interestingly, shotgun microbiota sequencing also showed that the HPV community in healthy woman is much more complex than previously defined, suggesting that co-existing non-oncogenic HPV viruses may stimulate or inhibit the oncogenic virus via viral interference or immune cross-reaction \[[@CR142]\].

Metabolome {#Sec20}
----------

Although not yet applied for diagnosing HPV or cervical (pre)cancerous lesions, metabolomics data were recently correlated with microbiome data in BV. Alterations in amino acid, carbohydrate, and lipid metabolism were associated with the presence and concentration of specific BV bacteria \[[@CR143]\]. Additionally, a dramatic loss of lactic acid and higher concentrations of mixed short chain fatty acids (SCFAs), including acetate, propionate, butyrate, and succinate, characterized BV \[[@CR144]\], and Nelson and coworkers \[[@CR145]\] reported on the importance of biogenic amines for dysbiosis and the outgrowth of BV-associated vaginal bacteria. If assays can be developed for the simple and rapid quantification of such microbiome and metabolome alterations, their combination with classical ELISA-like protein/peptide tests may lead to a simple yet very powerful diagnostic tool for detecting cervical cancer and its several precancerous stages.

Urine {#Sec21}
-----

Since CVF is washed away with the first flow of urine, it is expected that especially first-void urine contains most of the CVF components, including the mucus and debris from vaginal and cervical exfoliated cells. This may explain why the first collected part of a urine void collected with a special device (Colli-Pee™, Novosanis, Belgium) contains more human and HPV DNA than the subsequent parts \[[@CR146], [@CR147]\]. Moreover, self-sampling of urine for subsequent HPV DNA tests was very well accepted by patients \[[@CR148], [@CR149]\] and provided sensitivity for CIN2+ detection comparable to a physician-taken smear or brush-based self-sample \[[@CR150]\]. Several groups have attempted to identify urine components, other than HPV DNA, that could distinguish between healthy and precancerous states. The nature of these components varies from the hormone ratio \[[@CR151]\] and collagen abundance \[[@CR152]\] to host and/or viral gene methylation \[[@CR153], [@CR154]\]. However, although some of these studies show encouraging results, further validation is recommended with standardized protocols and higher patient numbers. Nevertheless, this does not exclude that biomarkers identified from experiments with CVF could be evaluated in urine and vice versa.

Alternative techniques {#Sec22}
----------------------

Although their complexity still prevents the development of self-tests or medical practice applications, several biophysical applications are currently being evaluated for high-throughput testing of CVF samples. Fourier transformed infrared spectroscopy (IR) was performed on 25 cervical vaginal lavage specimens from women referred for colposcopy \[[@CR155]\]. For the CIN III stage, the authors showed a strong correlation between IR spectra and histopathology; however, less precise matching was seen for lower CIN grades. Therefore, it is possible that the differences seen in IR spectroscopy reflect the molecular abnormalities in cervical cells during progression to cancer. If so, the technique may help in clinical decision making, but more studies are required to make this a routine technique in cervical cancer screening.

Additionally, mass spectrometry could contribute to cervical cancer diagnosis. The technology could very well be used in specialized laboratories where samples are collected, and it could complement or replace current methods, such as cytology and immunohistochemistry. However, at present, the main limitation of MS techniques lies in the sensitivity. For instance, to detect alpha-actinin-4, we used a targeted LC--MS technique called multiple reaction monitoring (MRM), but so far we have been unsuccessful because the limit of detection of the LC-Triple Quadrupole system for ACTN4 in CVF was at least ten-fold higher than the cutoff value of 18 pg/ml. Whether CVF contains cervical cancer biomarker proteins that are sufficiently high in abundance for detection by mass spectrometry remains to be elucidated, but at least for CVF labor biomarkers, Brown and co-workers \[[@CR156]\] showed that differences in proteome profiles were visible after protein separation on weak cation exchange chips and analysis using Surface-Enhanced Laser Desorption Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF--MS). Differences were attributed to fragments of alpha- or beta-hemoglobin. A fragment of alpha-hemoglobin was found to potentiate smooth muscle cell contraction in response to bradykinin, oxytocin and prostaglandin-F2alpha. Recently, Cricca et al. \[[@CR157]\] compared a commercial kit for HPV genotyping with a Matrix-Assisted Laser Desorption Ionization-Time Of Flight (MALDI-TOF) method, developed to genotype 16 high-risk human papillomavirus (HPV) types in cervical cytology specimens, and concluded that the MALDI-based method is well-suited for broad spectrum HPV genotyping in large-scale epidemiological studies. A very elegant integration of cytology/histology methods and molecular tests could come from MALDI-imaging whereby the mass spectrum is recorded from a thin tissue section, allowing for localization of different analytes to become visible. In this way, the distribution of many proteins and their expression profiles in cytological samples were correlated with the histological features and Pap groups, allowing for unbiased and automated classification of cervical Pap smears \[[@CR158]\].

Conclusion {#Sec23}
==========

In conclusion, several components residing in the cervical vaginal fluid are valuable candidate biomarkers for diagnostic tests for cervical cancer or its precancerous states. Since CVF and CVF-containing first-void urine are appropriate body fluids for use in self-tests or point-of-care tests, we could focus in the future on those biomarkers that lend itself to the development of such tests. Proteins are excellent candidates for this, and may originate from the virus, the tumor, the host immune system or the disturbed microbiome. For this, alpha-actinin-4 may offer a very good starting point, but we still have a way to go. Continued investigation is necessary to define a CVF/urine panel of biomarkers with which we can move forward to a standardized evaluation protocol such as in the PRoBE study design \[[@CR159]\]. Moreover, when the biomarker(s) should be used for clinical decisions, impact on patient outcome must also be evaluated with great care \[[@CR160]\].
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